Anti-Bestrophin/BEST1 antibody [EPR23926-112],Abcam,AB259836

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

ICC/IF, WB, IP, IHC-Fr

Platform ID

BAB223736906

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-Bestrophin/BEST1 antibody [EPR23926-112]
Cat. No.AB259836
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationICC/IF, WB, IP, IHC-Fr
ClonalityMonoclonal
Clone NumberEPR23926-112
Concentration0.601 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationPreservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Ligand-gated anion channel that allows the movement of anions across cell membranes when activated by calcium (Ca2+) (PubMed : 11904445, PubMed : 12907679, PubMed : 18179881, PubMed : 18400985, PubMed : 19853238, PubMed : 21330666, PubMed : 26200502, PubMed : 26720466, PubMed : 35789156). Allows the movement of chloride and hydrogencarbonate (PubMed : 11904445, PubMed : 12907679, PubMed : 18179881, PubMed : 18400985, PubMed : 19853238, PubMed : 21330666, PubMed : 26200502, PubMed : 26720466, PubMed : 35789156). Found in a partially open conformation leading to significantly smaller chloride movement (PubMed : 35789156). Upon F2R/PAR-1 activation, the sequestered calcium is released into the cytosol of astrocytes, leading to the (Ca2+)-dependent release of L-glutamate into the synaptic cleft that targets the neuronal postsynaptic GRIN2A/NMDAR receptor resulting in the synaptic plasticity regulation (By similarity). Upon activation of the norepinephrine-alpha-1 adrenergic receptor signaling pathway, transports as well D-serine than L-glutamate in a (Ca2+)-dependent manner, leading to activation of adjacent NMDAR receptors and therefore regulates the heterosynaptic long-term depression and metaplasticity during initial memory acquisition (By similarity). Releases the 4-aminobutanoate neurotransmitter in a (Ca2+)-dependent manner, and participates in its tonic release from cerebellar glial cells (By similarity). See full target information BEST1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.